January 30, 2018 04:39 PM EST
R&D
Pharma

Count­ing its re­main­ing cash, Vi­cal ax­es 40 staffers and cir­cles wag­ons around two Phase II as­sets

John Carroll

Editor & Founder

Just days af­ter Vi­cal $VI­CL and its part­ners at Astel­las an­nounced that their late-stage study of the CMV vac­cine ASP0113 had failed bad­ly, the …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

‭ Regulatory Lead / Head of Regulatory‬

Autonomy Bio Inc.

San Francisco, CA 94107, USA

TRENDING NOW

FDA de­lays PDU­FA date for small biotech, rais­ing ques­tions about im­pact of agency cuts

Pfiz­er launch­es a new wave of cost cuts, ex­pects $7.7B in to­tal sav­ings through 2027

FDA ap­proves Abeona’s skin dis­ease cell ther­a­py

With a new CEO, oligonu­cleotide biotech Crey­on forges Eli Lil­ly part­ner­ship

Oc­ta­gon Ther­a­peu­tics shuts down af­ter 'un­re­solved bi­ol­o­gy ques­tion­s'

sponsored

Rev­o­lu­tion­iz­ing obe­si­ty treat­ment: Could mi­to­chon­dria hold the key to un­lock­ing fat-spe­cif­ic weight loss?

A service from the Financial Times